LifeSciences BC > News > Member Announcements > Page 2

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participate in Eyevensys’ USD $30 Million Series B Financing for Development of Ocular Platform

January 8, 2020
Quark Venture LP

Vancouver, January 8, 2020 – Quark Venture LP and GF Securities participated in the USD $30 million Series B financing round announced today by Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic and retinal diseases. The investment, made through the Global Health Sciences (GHS) Fund, is part of the Series … Continue reading Global Health Sciences Fund (Quark Venture LP and GF Securities) Participate in Eyevensys’ USD $30 Million Series B Financing for Development of Ocular Platform

Qu Biologics’ Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

January 6, 2020

Vancouver, British Columbia – December 18, 2019 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce the completion of enrollment for the first stage of the RESTORE clinical trial, “A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of … Continue reading Qu Biologics’ Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 6, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share, which includes the exercise in full of the underwriters’ option to purchase 1,338,750 … Continue reading Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Generator 10.0 Call for Applications! Deadline: Feb 7th 2020

January 6, 2020
Discovery Parks

January 3rd, 2020 | Uncategorized Technology startup company in need of professional office space?  The Generator Challenge awards free furnished office space for 12 months to startups deemed most-likely to succeed and grow.  Application deadline: February 7, 2020. The Generator is a 5,000 square-foot co-location office space available to technology startup companies on a competitive basis. … Continue reading Generator 10.0 Call for Applications! Deadline: Feb 7th 2020

WAT Medical will attend 2020 CES to exhibit their innovative wearable technologies: EmeTerm, the anti-vomiting wrist band, and HeadaTerm, the anti-migraine head patch

December 20, 2019
WAT Medical

WAT Medical is a Canadian company that develops safe, effective, and user-friendly wearable medical devices. They focus on chronic and functional diseases and conditions. Their technologies use targeted neuromodulation to regulate specific nerve activities. The treatments are patient-oriented, with fixed parameters for individual conditions, and features excellent usability. Customers will receive personalized therapies according to … Continue reading WAT Medical will attend 2020 CES to exhibit their innovative wearable technologies: EmeTerm, the anti-vomiting wrist band, and HeadaTerm, the anti-migraine head patch

Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock

December 17, 2019
Neoleukin Therapeutics, Inc.

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering.  Neoleukin expects to grant the underwriters a 30-day … Continue reading Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock

Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering

December 17, 2019

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The aggregate gross proceeds from this offering are expected to be … Continue reading Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

December 12, 2019
InMed Pharmaceuticals Inc.

Vancouver, BC – December 9, 2019 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct a Phase 1 trial in the … Continue reading InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

December 12, 2019
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters’ option to purchase … Continue reading Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

December 9, 2019
Xenon Pharmaceuticals Inc.

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work Suggests Selective Sodium Channel Inhibitors that Reduce Action Potential Firing in Excitatory Neurons, While Sparing Inhibitory Interneurons, May Provide Promising Drug Profile … Continue reading Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting